Portal de Periódicos da CAPES

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK -rearranged non-small cell lung cancer

2018; European Respiratory Society; Volume: 51; Issue: 5 Linguagem: Inglês

10.1183/13993003.02431-2017

1399-3003

Jon Zugazagoitia, M. Biosca, Júlio Oliveira, M.E. Olmedo, Manuel Dómine, Ernest Nadal, J.C. Ruffinelli, N. Sánchez-Manjavacas Muñoz, A.M. Castro Luna, Berta Hernández, Maite Martínez, Iria Gallego, Eva Martínez de Castro, Carme Font, Virginia Calvo, Virginia Martínez-Marín, J. Corral, Esther Noguerón, Rebeca Mondéjar, Ignacio Escobar, C. Salvador Coloma, Óscar Juan, Manuel Sánchez Cánovas, Javier Valdivia, Manuel Ochoa, Rafael López Castro, Berta Obispo, Cristina Pangua, María Sereno, L. Fernández Franco, Xabier Mielgo-Rubio, Julia Calzas, Ana Blasco, Francisco Aparisi, L.E. Chara, Juan Francisco Grau-Béjar, Marta Soares, Ana Gómez, Víctor Zénzola, Marcial García-Morillo, Diego Cacho, Asunción Díaz-Serrano, Carlos Aguado, Santiago Ponce-Aix, J.L. González-Larriba, Andrés J. Muñoz Martín, David Lora, Luis Paz‐Ares, Aránzazu Manzano,

Lung Cancer Treatments and Mutations

Thromboembolic disease is fairly common in patients with lung cancer [1–3]. This incidence seems to be higher in patients with lung adenocarcinomas [4], with approximately 15% of those with advanced stage disease developing venous thromboembolisms (VTE) during the whole course of their disease [5–7]. Pulmonary adenocarcinomas are a heterogeneous group of diseases that can be stratified according to the presence of major oncogenic driver alterations. Anaplastic lymphoma kinase ( ALK ) rearrangements are detected in approximately 4% of these cases [8]. Isolated reports have suggested that patients bearing ALK -rearranged tumours might have a higher than expected incidence of thromboembolisms [9, 10]. In the present study, we have analysed the incidence, predictors and prognostic significance of thromboembolic events in a large, multi-institutional and homogeneous cohort of advanced stage patients with ALK -rearranged lung cancers from Spain and Portugal. Our primary objective was to estimate the incidence of thromboembolic events and their association with overall survival in these patients. High incidence and prognostic relevance of thromboembolic disease in patients with ALK-rearranged NSCLCs